Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Indian Journal of Forensic Medicine & Toxicology
Mustafa Al-Khyate1 , Zeina A.Althanoon2 , Nasih A.Alkazaz3
Unknown Affiliation
Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Adherence and Satisfaction of Deferasiroxversus Deferoxamine in Transfusion-Dependent Beta-Thalassemia Mustafa Al-Khyate1 , Zeina A.Althanoon2 , Nasih A.Alkazaz3
Indian Journal of Forensic Medicine & Toxicology Vol. 14 No. 4 (2020): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v14i4.11634

Abstract

Objectives: The present study was aimed to compare the adherence and satisfaction with deferoxamine(Desferal®) versus deferasirox (Exjade®), a novel oral iron chelator, in patients with transfusion-dependentbeta-thalassemia.Patients and Methods: In this cross?sectional, single-center study, 108 homozygous ?thalassemia majorpatients aged between 3-21 years old were enrolled. They were on regular blood transfusions and ironchelators (either deferoxamine or deferasirox) for about three months. Another fifty-six apparently healthynon-thalassemic subjects were enrolled as a control group. Results: Adherence and satisfaction wereassessedbyusing a simplequestionnaire establishedduring an interviewwithpatientsortheirparents.The serumferritinlevel was measuredbythe ELISAmethod.Our findings showed that adherence and satisfaction in the deferasirox group were more than that withdeferoxamine group patients. Serum ferritin level in the deferasirox group was significantly lower than inthe deferoxamine group at (p?0.001). while the control group was significantly lower than both patientsgroups at (p?0.001). Patients on deferasirox had lower adverse effects than the deferoxamine group sincedeferoxamine produce irritation and pain at the injection site for the patients.Conclusion: Our findings concluded that deferasirox is an effective iron chelator as deferoxamine but withbetter adherence and satisfaction than deferoxamine. Deferasirox can be used as a preferred iron chelatortherapy in iron-overload patients with beta-thalassemia.
Deleted Mustafa Al-Khyate1 , Zeina A.Althanoon2 , Nasih A.Alkazaz3
Indian Journal of Forensic Medicine & Toxicology Vol. 14 No. 4 (2020): Indian Journal of Forensic Medicine & Toxicology
Publisher : Institute of Medico-legal Publications Pvt Ltd

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37506/ijfmt.v14i4.12289

Abstract

xyz
Co-Authors